Press coverage about Cytori Therapeutics (NASDAQ:CYTX) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cytori Therapeutics earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.9445295928201 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several analysts recently weighed in on CYTX shares. ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, July 13th. Maxim Group set a $10.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a report on Wednesday, May 31st. Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Tuesday, July 11th. Finally, B. Riley downgraded Cytori Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, July 25th.

Cytori Therapeutics (CYTX) traded down 0.289% during mid-day trading on Wednesday, hitting $0.345. The company had a trading volume of 95,774 shares. Cytori Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.14. The company has a 50-day moving average price of $0.35 and a 200 day moving average price of $0.95. The company’s market capitalization is $11.98 million.

Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). Cytori Therapeutics had a negative net margin of 450.34% and a negative return on equity of 202.62%. The firm had revenue of $0.90 million for the quarter, compared to analysts’ expectations of $2.23 million. During the same quarter last year, the business earned ($0.43) earnings per share. The business’s revenue was down 18.2% compared to the same quarter last year. On average, analysts forecast that Cytori Therapeutics will post ($0.60) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/09/20/cytori-therapeutics-cytx-earns-media-sentiment-score-of-0-10.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Insider Buying and Selling by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.